article thumbnail

UK biotech sees worst funding downturn since 2012

pharmaphorum

Indeed, Initial Public Offerings (IPOs) raised just £28 million – the worst annual haul since 2012 – and, during the entirety of last year, UK biotech raised just £1.8 The post UK biotech sees worst funding downturn since 2012 appeared first on. billion, way down from £4.5 billion in 2021. billion raised.

article thumbnail

From Healing to Harm: The Unintended Consequences of Polypharmacy in Seniors

PharmD Live

The side effects can compound, resulting in a greater negative impact on a patient’s health than the individual effects of one medication alone. study in the Archives of Internal Medicine found that nearly 20% of older adults on new medications experienced a prescribing cascade (Archives of Internal Medicine, 2012). Campbell, N.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Ethnopharmacology: traditional medicine and modern drug discovery

Pharmaceutical Technology

For example, a widely referenced study from 2012 reported that up to 50% of approved drugs between 1981 and 2010 were directly or indirectly from natural products, while according to the WHO, 11% of drugs considered basic or essential originated from flowering plants.

article thumbnail

Bayer adds menopause drug to pipeline with KaNDy acquisition

pharmaphorum

A phase 3 trial is expected to begin in 2021 and the company says that the compound could generate peak sales of more than a billion euros globally. At the beginning of this year, KaNDy completed a phase 2b trial of its first-in-class drug NT-814, showing activity against symptoms of the menopause such as hot flashes and night sweats.

article thumbnail

New Approvals in 2022

Eye on FDA

Most notably in 2012 the Food and Drug Administration Safety and Innovation Act (FDASIA) was signed into law, bring to bear among other things, breakthrough therapy designation. But one could also surmise that AdComms are reserved for circumstances where FDA wants outside counsel because an investigative compound is exploring new territory.

article thumbnail

Dilution Protocol

RX Note

There would be no real difference in the information offered.

article thumbnail

Wave of Warning Letters to Foreign OTC Drug Manufacturing Facilities Following Remote Records Requests

FDA Law Blog: Biosimilars

Section 704(a)(4) was added to the FDCA by the Food and Drug Administration Safety and Innovation Action (FDASIA) in July 2012. Despite FDA having the authority to conduct paper inspections since the statutory provision was added to the FDCA by FDASIA in 2012, FDA did not issue a warning letter citing Section 704(a)(4) until January 2021.